Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital.

IF 0.4 Q4 HEALTH CARE SCIENCES & SERVICES Global & Regional Health Technology Assessment Pub Date : 2021-01-01 DOI:10.33393/grhta.2021.2202
Marco Chiumente, Alberto Russi, Federica Todino, Daniele Mengato, Marina Coppola, Melania Rivano, Angelo C Palozzo, Claudio Jommi
{"title":"Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital.","authors":"Marco Chiumente,&nbsp;Alberto Russi,&nbsp;Federica Todino,&nbsp;Daniele Mengato,&nbsp;Marina Coppola,&nbsp;Melania Rivano,&nbsp;Angelo C Palozzo,&nbsp;Claudio Jommi","doi":"10.33393/grhta.2021.2202","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Dose banding is an original approach that manages intravenous (IV) chemotherapy preparation by generating on a weekly basis a series of bags containing scaled dosages of the active agent. These predetermined, fixed dosage bags are intended to replace the traditional bags prepared daily that contain fully individualized dosages.</p><p><strong>Methods: </strong>Three different scenarios were examined: (1) the current method of daily preparation of individualized bags at the hospital pharmacy; (2) the weekly preparation at the hospital pharmacy of non-individualized bags containing discrete, predefined doses covering an adequate range of doses (dose banding); (3) the use of commercial ready-to-use bags based on the same approach of dose banding. The objective of this study was to compare these three different approaches in terms of cost per patient. We considered five cancer drugs (gemcitabine, oxaliplatin, paclitaxel, trastuzumab and 5-fluorouracil) that were suitable for the dose ranging approach. Appropriate dose bands for these five agents were identified. Costs were estimated for each of the three approaches.</p><p><strong>Results: </strong>A total of 13,490 fully individualized bags were studied, which corresponded to the real bags prepared at our institution for these five agents in 2018. Dose banding was predicted to determine savings ranging from €10,998 (-0.84%) for trastuzumab to €169,429.60 (-8.39%) for paclitaxel.</p><p><strong>Conclusion: </strong>The introduction of dose banding can determine economic savings along with other advantages, such as improved work conditions, management reorganization and containment of waste. The pharmaceutical industry can hopefully support these experiences by producing ready-to-use bags in predetermined dosages.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"8 ","pages":"29-34"},"PeriodicalIF":0.4000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/35/d4/grhta-8-29.PMC9616189.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global & Regional Health Technology Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33393/grhta.2021.2202","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 3

Abstract

Introduction: Dose banding is an original approach that manages intravenous (IV) chemotherapy preparation by generating on a weekly basis a series of bags containing scaled dosages of the active agent. These predetermined, fixed dosage bags are intended to replace the traditional bags prepared daily that contain fully individualized dosages.

Methods: Three different scenarios were examined: (1) the current method of daily preparation of individualized bags at the hospital pharmacy; (2) the weekly preparation at the hospital pharmacy of non-individualized bags containing discrete, predefined doses covering an adequate range of doses (dose banding); (3) the use of commercial ready-to-use bags based on the same approach of dose banding. The objective of this study was to compare these three different approaches in terms of cost per patient. We considered five cancer drugs (gemcitabine, oxaliplatin, paclitaxel, trastuzumab and 5-fluorouracil) that were suitable for the dose ranging approach. Appropriate dose bands for these five agents were identified. Costs were estimated for each of the three approaches.

Results: A total of 13,490 fully individualized bags were studied, which corresponded to the real bags prepared at our institution for these five agents in 2018. Dose banding was predicted to determine savings ranging from €10,998 (-0.84%) for trastuzumab to €169,429.60 (-8.39%) for paclitaxel.

Conclusion: The introduction of dose banding can determine economic savings along with other advantages, such as improved work conditions, management reorganization and containment of waste. The pharmaceutical industry can hopefully support these experiences by producing ready-to-use bags in predetermined dosages.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
静脉化疗袋的制备:意大利肿瘤医院剂量带法的评价。
剂量带是一种管理静脉(IV)化疗制剂的原始方法,通过每周产生一系列含有按比例剂量的活性剂的袋子。这些预定的、固定的剂量袋旨在取代每天制备的、含有完全个体化剂量的传统剂量袋。方法:考察三种不同的情况:(1)目前医院药房每日个体化药袋的制备方法;(2)每周在医院药房配制非个体化的药袋,药袋中装有离散的、预先确定的剂量,覆盖足够的剂量范围(剂量带);(3)使用基于相同剂量带的商业即用袋。本研究的目的是比较这三种不同的方法在每个病人的成本方面。我们考虑了五种适合剂量范围方法的抗癌药物(吉西他滨、奥沙利铂、紫杉醇、曲妥珠单抗和5-氟尿嘧啶)。确定了这五种药物的适当剂量范围。对这三种方法的成本进行了估计。结果:共研究了13490个完全个性化的袋子,与我所2018年为这5个代理人准备的真实袋子相对应。剂量分级预计将决定从曲妥珠单抗的10,998欧元(-0.84%)到紫杉醇的169,429.60欧元(-8.39%)的节省。结论:采用带剂量可以节约经济成本,并具有改善工作条件、整顿管理、遏制废物等优点。制药行业有望通过生产预先确定剂量的即用袋来支持这些经验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Global & Regional Health Technology Assessment
Global & Regional Health Technology Assessment HEALTH CARE SCIENCES & SERVICES-
CiteScore
0.80
自引率
20.00%
发文量
27
审稿时长
8 weeks
期刊介绍: Global & Regional Health Technology Assessment (GRHTA) is a peer-reviewed, open access journal which aims to promote health technology assessment and economic evaluation, enabling choices among alternative therapeutical paths or procedures with different clinical and economic outcomes. GRHTA is a unique journal having three different editorial boards who focus on their respective geographical expertise.
期刊最新文献
Analisi di costo-efficacia di brentuximab vedotin in combinazione con doxorubicina, vinblastina e dacarbazina (AVD) in pazienti adulti affetti da linfoma di Hodgkin in stadio IV. A 1-year per-patient cost of therapy administration analysis of mosunetuzumab and tisagenlecleucel in relapsed or refractory follicular lymphoma patients receiving two or more lines of systemic therapy. Impatto economico di dapagliflozin nella gestione della malattia renale cronica in Italia: risultati di un modello di micro-simulazione. Modello predittivo di policy per una migliore gestione della broncopneumopatia cronica ostruttiva: implicazioni economico-organizzative nel contesto sanitario italiano. A cost-effectiveness analysis of Navina Smart on adult patients affected by neurogenic bowel dysfunction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1